Phase-II study of BBR 2778, a new aza-anthracenedione, in patients with relapsed aggressive non-Hodgkin lymphomas.

被引：0
|
作者：
Borchmann, P
Morschhauser, F
Schnell, R
Harousseau, JL
Gisselbrecht, C
Rudolph, C
Wilhelm, M
Derigs, H
Kutz, K
Leynardier, D
Verdi, E
Camboni, G
Engert, A
机构：
[1] Univ Cologne, Innere Med Klin, Cologne, Germany
[2] Jop Huriez, Lille, France
[3] CHU Hotel Dieu, Serv Hematol, Nantes, France
[4] Hop St Louis, Serv Hematol, Paris, France
[5] Carl Diehm Klinikum Cottbus, Innere Med Klin, Cottbus, Germany
[6] Universitatsklin, Innere Med Klin, Wurzburg, Germany
[7] Hesper Ltd, Allschwil, Switzerland
[8] Novuspharma Spa, Monza, Italy
[9] Univ Mainz, Innere Med Klin, D-6500 Mainz, Germany
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1441
引用
收藏
页码：341A / 341A
页数：1
相关论文
共 50 条
  • [1] Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas
    Borchmann, P
    Morschhauser, F
    Parry, A
    Schnell, R
    Harousseau, JL
    Gisselbrecht, C
    Rudolph, C
    Wilhelm, M
    Derigs, HG
    Pfreundschuh, M
    Camboni, G
    Engert, A
    HAEMATOLOGICA, 2003, 88 (08) : 888 - 894
  • [2] Activity and safety of the new aza-anthracenedione BBR 2778 in patients with relapsed non-Hodgkin lymphomas.
    Borchmann, P
    Morschhauser, F
    Schnell, R
    Kutz, K
    Barbieri, P
    Camboni, GM
    Engert, A
    BLOOD, 2002, 100 (11) : 303B - 303B
  • [3] Phase-I study of BBR2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin lymphomas.
    Borchmann, P
    Knippertz, R
    Schnell, R
    Gamba, E
    Diehl, V
    Engert, A
    BLOOD, 1998, 92 (10) : 234B - 234B
  • [4] Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma
    Borchmann, P
    Schnell, R
    Knippertz, R
    Staak, JO
    Camboni, GM
    Bernareggi, A
    Hübel, K
    Staib, P
    Schulz, A
    Diehl, V
    Engert, A
    ANNALS OF ONCOLOGY, 2001, 12 (05) : 661 - 667
  • [5] Pharmacokinetics and clinical results of the new aza-anthracenedione BBR2778 in patients with advanced nonhodgkin lymphomas.
    Borchmann, P
    Knippertz, R
    Schnell, R
    Camboni, G
    Bernareggi, A
    Diehl, V
    Engert, A
    BLOOD, 1999, 94 (10) : 258B - 258B
  • [6] Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas
    El-Helw, Loaie M.
    Hancock, Barry W.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (10) : 1683 - 1691
  • [7] A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies
    Faivre, S
    Raymond, E
    Boige, V
    Gatineau, M
    Buthaut, X
    Rixe, O
    Bernareggi, A
    Camboni, G
    Armand, JP
    CLINICAL CANCER RESEARCH, 2001, 7 (01) : 43 - 50
  • [8] Phase I study of BBR-2778 in BSHAP for relapsed aggressive non-Hodgkin's lymphoma (NHL)
    Levine, A
    Fayad, L
    Modiano, M
    Camboni, G
    Cabinallas, F
    EXPERIMENTAL HEMATOLOGY, 2003, 31 (07) : 110 - 110
  • [9] Preliminary phase II study results of BBR2778 in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma.
    Herbrecht, R
    Borchmann, P
    Wilhelm, M
    Morschhauser, F
    Hess, G
    Kutz, K
    Comis, S
    Laffranchi, BL
    Engert, A
    BLOOD, 2004, 104 (11) : 682A - 683A
  • [10] A phase I study of pixantrone (BBR 2778) in combination with cyclophosphamide, vincristine and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma.
    Borchmann, P
    Schnell, R
    Morschhauser, F
    Hess, G
    Harousseau, JL
    Herbrecht, R
    Derigs, HG
    Dreyfus, F
    Schouten, HC
    Engert, A
    Camboni, G
    BLOOD, 2003, 102 (11) : 642A - 642A
12345